The Effect of Renin-Angiotensin Blockers on COVID-19 Related Mortality: A Tertiary Center’s Experience
Cor et Vasa
; 64(3):277-281, 2022.
Article
in English
| EMBASE | ID: covidwho-1970030
ABSTRACT
Background:
The first reports on coronaviruse disease 2019 (COVID-19) revealed an exaggerated mortality rate in hypertensive patients. In this regard, concerns about angiotensin-converting enzyme (ACE) inhibitors’ and angiotensin-receptor blockers’ (ARBs) have been aroused. Our aim in this study was to evaluate the potential bad outcome effect of hypertension and anti-hypertensive therapy on COVID-19.Methods:
183 patients with polymerase-chain-reaction (PCR)-proven COVID-19, who were admitted to our hospital and consulted to cardiology department between 15th of March and 15th of April 2020 were included. Data were recruited from hospital records.Results:
Thirty-two out of 183 patients with COVID-19 died in hospital. Hypertension incidence was not statistically different between patients who survived and died (76 [50.3%] vs 19 [59.4%, p = 0.352]). Although the usage rate of ACEI were similar among groups, ARB usage rate was significantly higher in patients who died than survived (11 [34.4%] vs 23 [15.2%], p = 0.011). Binary regression analysis showed an association between ARBs and mortality (OR 0.032, 95% CI 1.045–2.623, p = 0.032).Conclusion:
Our study confirmed previous concerns regarding a potential harmful effects of ARBs on COVID-19 related mortality.
adult; antihypertensive therapy; article; cardiology; controlled study; coronavirus disease 2019; female; hospital mortality; human; hypertension; incidence; major clinical study; male; medical record; mortality; outcome assessment; pandemic; protein function; angiotensin; angiotensin receptor antagonist; dipeptidyl carboxypeptidase; endogenous compound; renin
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
Language:
English
Journal:
Cor et Vasa
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS